INmune Bio, Inc.
INmune Bio, Inc. (INMB) Revenue
Annual & quarterly revenue history · segment & region breakdown
INMB · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsINmune Bio, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 257.14% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +257.14% |
| 2024-12-31 | $0.00B | -$0.00B | -90.97% |
| 2023-12-31 | $0.00B | -$0.00B | -58.56% |
| 2022-12-31 | $0.00B | +$0.00B | +106.63% |
| 2021-12-31 | $0.00B | +$0.00B | +1545.45% |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income INmune Bio, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
INmune Bio, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from INmune Bio, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
INMB revenue · 4 questionsINMB's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 257.14% year-over-year from $0.00B in FY2025.
▸ Source: FMP · INmune Bio, Inc. SEC filings · GAAP · INmune Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026